AstraZeneca To Buy Amolyt Pharma for $1.05B To Expand Rare Disease Pipeline

Key TakeawaysAstraZeneca PLC is acquiring Amolyt Pharma for $1.05 billion to strengthen its pipeline for rare diseases, particularly hypoparathyroidism.The deal includes an upfront payment of $800 million with a potential additional payment of $250 million, contingent on meeting regulatory approvals.AstraZeneca said it expects the deal to close by the end of the third quarter of 2024. AstraZeneca PLC (AZN) plans to acquire biotech firm Amolyt Pharma for $1.05 billion in cash, the drugmaker said Thursday, bo ...